H.R. 1905: Selling Bricks and Mortar to Congress

CAN’T AFFORD IT The proper priorities for NSF remain people, equipment and facilities, in that order. Thus, any new program must be viewed in the context of all established programs and evaluated in competition with other high-priority activities. To do otherwise does not accept the reality of the overall budget situation, and at the risk of compromising the standards of excellence we have worked so hard to maintain. Thus, while we support much of the intent and spirit of H.R. 1905, we m

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The proper priorities for NSF remain people, equipment and facilities, in that order. Thus, any new program must be viewed in the context of all established programs and evaluated in competition with other high-priority activities. To do otherwise does not accept the reality of the overall budget situation, and at the risk of compromising the standards of excellence we have worked so hard to maintain. Thus, while we support much of the intent and spirit of H.R. 1905, we must oppose the bill. With its very large authorization, the bill simply cannot be accommodated within the current fiscal climate.

—Erich Bloch
Director, National Science Foundation

Establishing a research facilities program under the National Science Foundation... has the advantage of being sharply focused on the problem of inadequate facilities . . with administration being placed under one agency. . . . [the bill] represents a good start on addressing the research ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies